Tin tức & Cập nhật

Treatment with the Janus kinase (JAK) 1 inhibitor povorcitinib results in significant repigmentation of the body and face in adult patients with extensive nonsegmental vitiligo (NSV), with an acceptable safety profile, through 52 weeks, reports a phase II study.

In a large cross-sectional study evaluating individuals hospitalized for respiratory syncytial virus (RSV), influenza, and COVID-19, one in 10 patients hospitalized for RSV had a concurrent acute cardiovascular (CV) event, and the odds of cardiac events were substantially higher in RSV vs COVID-19 hospitalizations.